[Scopolamine butylbromide (0.2 mg.kg-1) prevents succinylcholine-induced bradycardia in infants and children].
We evaluated the effectiveness of scopolamine butylbromide in preventing succinylcholine-induced bradycardia in infants and children. Forty-two infants and children were randomly assigned into two groups. In group I, 0.2 mg.kg-1 and in group II, 0.4 mg.kg-1 of scopolamine butylbromide in mixture with succinylcholine (2 mg.kg-1) was administered after halothane induction. HR decreased significantly after halothane induction. Following the injection of the mixture, HR increased above the preinduction value within 20 seconds without any decrease in HR. HR changes were identical in the two groups. In conclusion, scopolamine butylbromide (0.2 mg.kg-1) was effective in preventing succinylcholine-induced bradycardia in infants and children.
Tsuji
M H
MH
Department of Anesthesiology, Ibaraki Children's Hospital, Mito.
Yamashita
M
M
D001919:Bradycardia / Q000139:chemically induced / Q000517:prevention & control*; D002086:Butylscopolammonium Bromide / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D013390:Succinylcholine / Q000009:adverse effects*
D002086:Butylscopolammonium Bromide; D013390:Succinylcholine